ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

Gilead Sciences division Kite is aiming for its bicistronic anti-CD19/CD20 CAR-T therapy KITE-363 to be able to both tamp down toxicity in patients with B-cell lymphomas and to prevent CD19-negative relapses, a persistent problem with CAR-T cell therapies that target CD19 such as Gilead’s Yescarta (axicabtagene ciloleucel).

Key Takeaways

KITE-363 is designed to be able to overcome CD19 antigen-negative relapse and also lower toxicity and improve persistence thanks to its bicistronic design incorporating dual antigen targeting and dual costimulatory domains.

On May 30 at the American Society of Clinical Oncology (ASCO) meeting in Chicago, the drugmaker presented data from its...